Ascendis Pharma A/S (NASDAQ:ASND) headquartered in Hellerup, will host a conference call for the investment community to discuss the 2Q20 financial results on 27th August 2020 at 4:30 PM Eastern Time.
The conference call will also be webcast live under the investor relations section of the website edge.media-server.com/mmc/p/w7hnzp6j
To participate on the live call, please dial 844-290-3904 or 574-990-1036 Outside U.S., with passcode : 9987362
Earnings Expectation
Ascendis Pharma A/S is reporting second quarter financial results on Thursday 27th August 2020, after market close.
According to analysts surveyed by Thomson Reuters, ASND is expected to report 2Q20 loss of $ 1.71 per share from revenue of $ 2.53 million.
For the full year, analysts anticipate top line of $ 11.31 million, while looking forward to loss of $ 6.68 per share bottom line.
Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon human growth hormone, which has completed Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone has completed Phase I clinical study for treating hypoparathyroidism; and TransCon CNP, a long-acting prodrug of C-type natriuretic peptide for the treatment of achondroplasia. It is also developing preclinical studies in the field of oncology for potential product candidates and evaluate systemic and localized delivery systems using its TransCon technologies.
